Literature DB >> 15962362

Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells.

Jian-Yong Zheng1, Guang-Shun Yang, Wei-Zhong Wang, Jiang Li, Kai-Zong Li, Wen-Xian Guan, Wen-Liang Wang.   

Abstract

AIM: To investigate the role of overexpression of Bax in apoptotic pathways and the response of human hepatocellular cancer (HCC)-9204 cells to cell death induced by adriamycin.
METHODS: The whole length of Bax cDNA was transfected into human HCC-9204 cells by the method of lipofectamine transfection. An inducible MT-II regulatory system was constructed, which allowed controlled expression of protein upon addition of ZnSO4 (100 micromol/L) as an external inducer. Stable transfecting inducible expression vector containing Bax gene was performed. Expression of Bax in protein was analyzed by immunohistochemistry and Western blotting. TUNEL and flow cytometry were used to assess the effect of Bax on apoptosis. Colony assay and tetrazolium blue (MTT) assay were used to evaluate the difference in drug sensitivity of HCC-9204 cells after Bax-transfection.
RESULTS: Immunohistochemistry and Western blotting demonstrated that the expression of Bax protein markedly increased in Bax-transfected cells 4 h after the addition of ZnSO4. Bax positive signal was frequently found on the cytoplasm and perinuclear region of HCC-9404 cells, and there was ectopic expression in cells with marked condensation of chromatin and cytoplasm (apoptotic cells). Apoptotic index significantly increased in Bax-transfected HCC-9204/Bax cells (3.6 vs 27.2, 4.2 vs 32.3, P<0.05). Flow cytometry analysis showed a significant sub-G1 peak and apoptosis in 15.4% HCC-9204/Bax cells 24 h after treatment. Furthermore, colony survival rate decreased from 66% (HCC-9204/pMD) to 45% (HCC-9204/Bax) 2 d after ADR withdrawal. MTT assay result showed that the effects of Bax on cell viability following ADR exposure were significant as compared to the vehicle-transfected HCC-9204/pMD cells (21% vs 44%, P<0.01).
CONCLUSION: Overexpression of Bax not only induces apoptosis, but also sensitizes HCC-9204 cells to cell death induced by adriamycin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962362      PMCID: PMC4315948          DOI: 10.3748/wjg.v11.i23.3498

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.

Authors:  Grant Dewson; Roger T Snowden; Jason B Almond; Martin J S Dyer; Gerald M Cohen
Journal:  Oncogene       Date:  2003-05-01       Impact factor: 9.867

2.  Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents.

Authors:  T Kobayashi; S Ruan; K Clodi; K O Kliche; H Shiku; M Andreeff; W Zhang
Journal:  Oncogene       Date:  1998-03-26       Impact factor: 9.867

3.  Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas.

Authors:  W Beerheide; Y J Tan; E Teng; A E Ting; A Jedpiyawongse; P Srivatanakul
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

4.  Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).

Authors:  Rajani Ravi; Atul Bedi
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

5.  p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin.

Authors:  V Lam; J P McPherson; L Salmena; J Lees; W Chu; E Sexsmith; D W Hedley; M H Freedman; J C Reed; D Malkin; G J Goldenberg
Journal:  Leuk Res       Date:  1999-10       Impact factor: 3.156

6.  Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells.

Authors:  S Gamen; A Anel; P Pérez-Galán; P Lasierra; D Johnson; A Piñeiro; J Naval
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

7.  Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice.

Authors:  Christine M Eischen; Jerold E Rehg; Stanley J Korsmeyer; John L Cleveland
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

8.  Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis.

Authors:  C F Gao; S Ren; L Zhang; T Nakajima; S Ichinose; T Hara; K Koike; N Tsuchida
Journal:  Exp Cell Res       Date:  2001-04-15       Impact factor: 3.905

9.  Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin.

Authors:  Theocharis Panaretakis; Katja Pokrovskaja; Maria C Shoshan; Dan Grandér
Journal:  J Biol Chem       Date:  2002-08-21       Impact factor: 5.157

10.  Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells.

Authors:  T Kobayashi; H Sawa; J Morikawa; W Zhang; H Shiku
Journal:  Jpn J Cancer Res       Date:  2000-12
View more
  4 in total

1.  The Protection of Zinc against Acute Cadmium Exposure: A Morphological and Molecular Study on a BBB In Vitro Model.

Authors:  Jacopo J V Branca; Donatello Carrino; Ferdinando Paternostro; Gabriele Morucci; Claudia Fiorillo; Claudio Nicoletti; Massimo Gulisano; Carla Ghelardini; Lorenzo Di Cesare Mannelli; Matteo Becatti; Alessandra Pacini
Journal:  Cells       Date:  2022-05-15       Impact factor: 7.666

2.  Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.

Authors:  Stephanie E Areloegbe; Mmenyene U Peter; Mosunmola B Oyeleke; Kehinde S Olaniyi
Journal:  BMC Endocr Disord       Date:  2022-09-07       Impact factor: 3.263

3.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

4.  Designing combination therapies with modeling chaperoned machine learning.

Authors:  Yin Zhang; Julie M Huynh; Guan-Sheng Liu; Richard Ballweg; Kayenat S Aryeh; Andrew L Paek; Tongli Zhang
Journal:  PLoS Comput Biol       Date:  2019-09-09       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.